Results 171 to 180 of about 6,366 (244)

Real‐World Outcomes of Thromboprophylaxis With Apixaban in Patients With Newly Diagnosed Multiple Myeloma, the MyelMeXa Study

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Multiple myeloma (MM) carries a high venous thromboembolism (VTE) risk; aspirin shows limited efficacy, while factor‐Xa inhibitors show promise. Objectives Evaluate apixaban for primary thromboprophylaxis in newly diagnosed MM (NDMM).
K. Alexandra Sanchez, Gabriela Cesarman‐Maus, Michelle Flores‐Cruz, Beatriz Cabello, Ramiro Espinoza, Omar Eduardo Fernandez‐Vargas   +5 more
wiley   +1 more source

The Role of N6‐Methyladenosine Modification in Health and Disease

MedComm, Volume 7, Issue 6, June 2026.
N6‐methyladenosine (m6A) is the most prevalent internal RNA modification in eukaryotes, acting as a pivotal epitranscriptomic regulator of RNA metabolism. This modification plays a dual role: it maintains physiological homeostasis under normal conditions but drives disease progression when dysregulated.
Linghuan Li, Yuanhai Sun, Wanfang Zheng, Lingqin Li, Yaqian Feng, Minyou Qi, Hanbing Li   +6 more
wiley   +1 more source

Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies

MedComm, Volume 7, Issue 6, June 2026.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by unleashing antitumor immunity. This review comprehensively examines the molecular mechanisms underlying key immune checkpoints—including PD‐1/PD‐L1, CTLA‐4, and TIM‐3—and their clinical applications.
Qintao Ge, Liu Yu, Jiahe Lu, Aihetaimujiang Anwaier, Xiyue Xiao, Yonghao Chen, Dingwei Ye, Hailiang Zhang, Wenhao Xu, Wenbin Dai   +9 more
wiley   +1 more source

Short‐Term, Cycle‐Synchronized Adjunctive Therapy With Crocus Total Glucosides Tablets for Cardiac Protection Against Cancer Therapy‐Related Cardiac Dysfunction in Breast Cancer Patients: A Randomized, Double‐Blind, Placebo‐Controlled Trial

MedComm, Volume 7, Issue 6, June 2026.
Cycle‐synchronized CTGT therapy attenuates LVGLS decline and reduces CTRCD in breast cancer patients. This randomized, double‐blind, placebo‐controlled trial assessed whether cycle‐synchronized CTGT prevent CTRCD in 120 breast cancer patients receiving chemotherapy.
Xiaoling Liu, Mengmeng Li, Wenwen Song, Yu Zhang, Wuyun Bao, Chaoyu Liu, Yuan Zhang, Quande Liu, Cheng Zhang, Yun Zhang, Li Li, Mei Zhang   +11 more
wiley   +1 more source

Inflammation, Immunity, and Cardiovascular Diseases

Med Research, Volume 2, Issue 2, Page 343-370, June 2026.
Cardiovascular stress signals (e.g., hemodynamic shear, oxidized lipids, and ischemia) act on endothelial and immune cells to activate and amplify inflammation through NF‐κB, the NLRP3 inflammasome, and JAK/STAT signaling, inducing proinflammatory cytokines/chemokines (IL‐6, IL‐1β, TNF‐α, and CCL2) and self‐amplifying circuits; clinically, inflammatory
Dezhi Guo, Yan Liao, Rui Zhao, Zhaoyu Li, Kaikai Wang, Haoling Zhang, Pingxin Sun, Yadong Guo, Wangzheqi Zhang   +8 more
wiley   +1 more source

The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Autophagy is a conserved cellular process degrading dysfunctional organelles and protein aggregates to maintain cell homeostasis, and it exhibits context‐dependent duality in cancer. Autophagy functions as a critical tumor‐suppressive mechanism by preventing DNA damage and mutation during tumor initiation.
Xiang‐Zheng Gao, Yuheng Qin, Haoyu Wan, Guang Lu, Han‐Ming Shen   +4 more
wiley   +1 more source

Theranostic Advancements in Brain Cancer: Promising Approaches for Emerging Therapy

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Strategies for improving intra‐arterial administration (A) and photodynamic therapy in brain cancer (B). Improving intra‐arterial (IA) administration and photodynamic therapy (PDT) for brain cancer involves enhancing tumor targeting and breaching the blood–brain barrier (BBB). Key strategies include super selective catheterization, using osmotic agents
Bipraban Khanra, Manoj Kumar Sarangi
wiley   +1 more source

Gold Nanoparticle–Trastuzumab Conjugates for HER2‐Positive Breast Cancer Treatment: Developments in Radionuclide Therapy, Multimodal Imaging, and Combination Strategies

Nano Select, Volume 7, Issue 6, June 2026.
ABSTRACT This work comprehensively examines recent advances in the treatment of human epidermal growth factor receptor 2 (HER2)‐positive breast cancer using trastuzumab‐conjugated gold nanoparticles (AuNPs). By analyzing several pivotal studies, it explores how these nanoplatforms enhance therapeutic specificity and efficacy while minimizing systemic ...
Tara Tarzi, Zhina Pazhouhesh, Danial Heyrati, Amir Mohammad Ghanbari Zarmehri, Ali Es‐haghi, Mohammad Ehsan Taghavizadeh Yazdi   +5 more
wiley   +1 more source

Effects of Exercise on Cancer‐Related Cognitive Impairment: An Umbrella Review of Systematic Reviews and Meta‐Analysis

Psycho-Oncology, Volume 35, Issue 6, June 2026.
ABSTRACT Background Cancer‐related cognitive impairment (CRCI) is a common consequence of cancer and its treatments, with mild but significant deficits in memory, attention or executive function. These symptoms negatively affect survivors' quality of life, daily functioning, and return to work.
Francisco Gómez‐Almeida, Daniel González‐Devesa, Clara Gacparski, Cristina Nombela, Oscar L. Veiga   +4 more
wiley   +1 more source

6‐Shogaol Attenuates Doxorubicin‐Induced Cardiac and Skeletal Muscle Atrophy by Inhibiting E3 Ubiquitin Ligases and Necroptosis

Phytotherapy Research, Volume 40, Issue 6, Page 3132-3149, June 2026.
Doxorubicin induces cardiac and skeletal muscle atrophy by upregulating E3 ubiquitin ligases, inhibiting myogenic regulatory factors, and activating necroptosis. Cardiac atrophy can further exacerbate cardiotoxicity. 6‐Shogaol negatively regulates these processes and attenuates doxorubicin‐induced cardiac and skeletal muscle atrophy.
Xipeng Sun, Yaxian Wang, Quanjun Yang, Bo Xin, Jinlu Huang, Cheng Guo   +5 more
wiley   +1 more source